Establishment of a biosafe murine model of skeletal tuberculosis using Mycobacterium smegmatis

Abstract

Background: Skeletal tuberculosis (TB) remains a persistent clinical and research challenge due to its chronic course, osteolytic destruction, and the limitations of existing animal models, which often require high-level biosafety containment or fail to replicate human skeletal pathology.

Methods: This study developed a biosafe, accessible, and versatile murine model of skeletal TB using Mycobacterium smegmatis, a fast-growing, nonpathogenic mycobacterial species with high genomic homology to Mycobacterium tuberculosis. Three infection routes—subperiosteal calvarial injection, intratibial injection, and intracardiac inoculation—were systematically evaluated for their ability to induce localized versus disseminated bone infection under standard biosafety level (BSL)-1 conditions.

Results: Subperiosteal calvarial and intratibial injection of M. smegmatis induced localized bone lesions characterized by osteolysis, sequestrum formation, granulomatous inflammation, and increased osteoclast activity. Intratibial infection additionally triggered compartment-specific immune responses, including neutrophil and macrophage expansion, transient B-cell depletion, and activation of interferon-γ⁺ (IFN-γ⁺) T cells, reflecting active immune remodeling at the infection site. Systemic dissemination via intracardiac injection reproducibly generated progressive vertebral and tibial bone destruction with organized granuloma formation and immune cell infiltration but without prominent sequestrum formation. Compared to intratibial infection, intracardiac delivery exhibited lower intragroup variability and more closely recapitulated the diffuse progression of extrapulmonary skeletal tuberculosis.

Conclusions: This M. smegmatis–based murine model provides a straightforward, reliable, and immunopathologically relevant platform for exploring host–pathogen dynamics, immune-driven bone destruction, and early-stage therapeutic testing in skeletal TB, all within standard BSL-1 laboratories. This model fills a critical gap by enabling BSL-1 research into skeletal TB mechanisms and drug development.

Keywords

bone tuberculosis / murine model / Mycobacterium smegmatis / tuberculosis

References

[1] World Health Organization. WHO Consolidated Guidelines on Tuberculosis. Module 2: Screening-Systematic Screening for Tuberculosis Disease. World Health Organization; 2021.

[2] Chiang CY, Van Weezenbeek C, Mori T, Enarson DA. Challenges to the global control of tuberculosis. Respirology. 2013; 18(4): 596-604.

[3] Bagcchi S. WHO's global tuberculosis report 2022. Lancet Microbe. 2023; 4(1):e20.

[4] World Health Organization. Global Tuberculosis Report 2024. World Health Organization; 2024: 1-68.

[5] Li T, Yan X, Du X, et al. Extrapulmonary tuberculosis in China: a national survey. Int J Infect Dis. 2023; 128: 69-77.

[6] Leonard MK, Blumberg HM. Musculoskeletal tuberculosis. Tuberculosis and Nontuberculous Mycobacterial Infections. Wiley; 2017: 371-392.

[7] Rodriguez-Takeuchi SY, Renjifo ME, Medina FJ. Extrapulmonary tuberculosis: pathophysiology and imaging findings. Radiographics. 2019; 39(7): 2023-2037.

[8] Shrestha OP, Sitoula P, Hosalkar HS, Banskota AK, Spiegel DA. Bone and joint tuberculosis. Univ Pa Orthop J. 2010; 20: 23-28.

[9] Pigrau-Serrallach C, Rodríguez-Pardo D. Bone and joint tuberculosis. Eur Spine J. 2013; 22: 556-566.

[10] Procopie I, Popescu EL, Huplea V, et al. Osteoraticular tuberculosis-brief review of clinical morphological and therapeutic profiles. Curr Health Sci J. 2017; 43(3): 171-190.

[11] Weeratunga P, Moller DR, Ho L-P. Immune mechanisms of granuloma formation in sarcoidosis and tuberculosis. J Clin Invest. 2024; 134(1):e175264.

[12] Rammeh Rommani S, Romdhane E. Pathology of bone and joint tuberculosis. Histopathology of Bone and Joint Infections. Springer; 2024: 133-149.

[13] Vekszler G, Granner M, Nebot Valenzuela E, et al. Microarchitecture of historic bone samples with tuberculosis. Wien Klin Wochenschr. 2022; 134(11): 449-457.

[14] Plumlee CR, Duffy FJ, Gern BH, et al. Ultra-low dose aerosol infection of mice with Mycobacterium tuberculosis more closely models human tuberculosis. Cell Host Microbe. 2021; 29(1): 68-82.

[15] Li H, Cao W, Chen S, Chen J, Xing Y, Yang H. Comparative interleukins and chemokines analysis of mice mesenchymal stromal cells infected with Mycobacterium tuberculosis H37Rv and H37Ra. Arch Biochem Biophys. 2023; 744:109673.

[16] Freyne B, Marchant A, Curtis N. BCG-associated heterologous immunity, a historical perspective: experimental models and immunological mechanisms. Trans R Soc Trop Med Hyg. 2015; 109(1): 46-51.

[17] Liang YC, Berton S, Reeks C, Sun J. An in vivo biosafety-level-2-compatible model of Mycobacterium tuberculosis infection for drug susceptibility testing. STAR Protoc. 2022; 3(3):101575.

[18] Venketaraman V, Millman A, Salman M, et al. Glutathione levels and immune responses in tuberculosis patients. Microb Pathog. 2008; 44(3): 255-261.

[19] Kent ML, Watral V, Wu M, Bermudez LE. In vivo and in vitro growth of Mycobacterium marinum at homoeothermic temperatures. FEMS Microbiol Lett. 2006; 257(1): 69-75.

[20] Sous C, Frigui W, Pawlik A, et al. Genomic and phenotypic characterization of Mycobacterium tuberculosis' closest-related non-tuberculous mycobacteria. Microbiol Spectr. 2024; 12(6):e04126-23.

[21] Sparks IL, Derbyshire KM, Jacobs JWR, Morita YS. Mycobacterium smegmatis: the vanguard of mycobacterial research. J Bacteriol. 2023; 205(1):e00337-22.

[22] Nakedi KC, Nel AJM, Garnett S, Blackburn JM, Soares NC. Comparative Ser/Thr/Tyr phosphoproteomics between two mycobacterial species: the fast growing Mycobacterium smegmatis and the slow growing Mycobacterium bovis BCG. Front Microbiol. 2015; 6:237.

[23] Tyagi JS, Sharma D. Mycobacterium smegmatis and tuberculosis. Trends Microbiol. 2002; 10(2): 68-69.

[24] Lelovic N, Mitachi K, Yang J, Lemieux MR, Ji Y, Kurosu M. Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis. J Antibiot. 2020; 73(11): 780-789.

[25] Wang R, Marcotte EM. The proteomic response of Mycobacterium smegmatis to anti-tuberculosis drugs suggests targeted pathways. J Proteome Res. 2008; 7(3): 855-865.

[26] Ranjitha J, Rajan A, Shankar V. Features of the biochemistry of Mycobacterium smegmatis, as a possible model for Mycobacterium tuberculosis. J Infect Public Health. 2020; 13(9): 1255-1264.

[27] Dou C, Cao Z, Ding N, et al. Cordycepin prevents bone loss through inhibiting osteoclastogenesis by scavenging ROS generation. Nutrients. 2016; 8(4):231.

[28] Alder KD, Lee I, Munger AM, et al. Intracellular Staphylococcus aureus in bone and joint infections: a mechanism of disease recurrence, inflammation, and bone and cartilage destruction. Bone. 2020; 141:115568.

[29] Nobre RN, Esteves AM, Borges N, et al. Production and purification of phosphatidylinositol mannosides from Mycobacterium smegmatis biomass. Curr Protoc. 2022; 2(6):e458.

[30] Bloom BR, Fine PEM. The BCG experience: implications for future vaccines against tuberculosis. Tuberculosis: pathogenesis, Protection, and Control. Wiley; 1994: 531-557.

[31] Venugopal V, Ng DC-E. Bacille Calmette-Guérin (BCG) osteomyelitis: a rare complication of BCG vaccination. BMJ Case Rep CP. 2024; 17(9):e261058.

[32] Deng J, Yang Y, He J, et al. Vitamin D receptor activated by vitamin D administration alleviates Mycobacterium tuberculosis-induced bone destruction by inhibiting NFκB-mediated aberrant osteoclastogenesis. FASEB J. 2021; 35(6):e21543.

[33] Jia Y, Zhang F, Meng X, et al. Osteocytes support bone metastasis of melanoma cells by CXCL5. Cancer Lett. 2024; 590:216866.

[34] Lyadova IV. Neutrophils in tuberculosis: heterogeneity shapes the way? Mediat Inflamm. 2017; 2017(1):8619307.

[35] Phuah J, Wong EA, Gideon HP, et al. Effects of B cell depletion on early Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun. 2016; 84(5): 1301-1311.

RIGHTS & PERMISSIONS

2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.